Business
Aligos is a clinical-stage biotechnology company developing therapeutics for liver diseases and viral infections, including chronic HBV, MASH, obesity, and coronavirus infections.
Aligos revenue fell to $2.2M, cash burn remained about $82.5M, but net loss narrowed sharply.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage liver and antiviral pipelineWatch
- Revenue — Revenue fell 39.5% to $2.2MWatch
- Profitability — Net loss narrowed to $24.2MNote
- Cash — Cash from ops was -$82.5MWatch
- Balance sheet — Equity improved to $53.5MOK
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; other scores unavailableWatch
Leadership changes
From Aligos Therapeutics, Inc.'s own filings, the day they're filed.
- Nikhil Aneja · Principal Accounting Officer · appointmenteff. 2026-01-29
- Lesley Ann Calhoun · Chief Operating Officer · appointmenteff. 2025-01-30
- Matthew McClure · Chief Medical Officer · departureeff. 2024-05-09
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-26
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aligos Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.